Search
Dotinurad
go.drugbank.com/drugs/DB16145InvestigationalDotinurad is under investigation in clinical trial NCT03372200 (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).
(R)-acetoin
go.drugbank.com/drugs/DB04364ExperimentalIt is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
Synonyms: (R)-2-acetoin, (R)-acetoin(S)-acetoin
go.drugbank.com/drugs/DB02788ExperimentalIt is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
Lanifibranor
go.drugbank.com/drugs/DB14801InvestigationalLanifibranor is under investigation in clinical trial NCT03008070 (Phase 2b Study in NASH to Assess IVA337).
Chiglitazar
go.drugbank.com/drugs/DB19023InvestigationalChiglitazar is under investigation in clinical trial NCT06125587 (Chiglitazar/metformin in Non-obese Women With PCOS).
Synonyms: O-(2-(9h-carbazol-9-yl)ethyl)-n-(2-(4-fluorobenzoyl)phenyl)-l-tyrosine, L-tyrosine, o-(2-(9h-carbazol-9-yl)ethyl)-n-(2-(4-fluorobenzoyl)phenyl)-Temanogrel
go.drugbank.com/drugs/DB05227InvestigationalAPD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. … APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.
Brazikumab
go.drugbank.com/drugs/DB16115InvestigationalBrazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).
Deudomperidone
go.drugbank.com/drugs/DB19055InvestigationalDeudomperidone is under investigation in clinical trial NCT05832151 (A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis).
Nitarsone
go.drugbank.com/drugs/DB11437ExperimentalVet approvedNitarsone is an organoarsenic compound. It is used as an additive in poultry feed to improve weight gain and feed efficiency, while preventing blackhead disease. … It is marketed as Histostat by Zoetis, a publicly traded subsidiary of Pfizer.
IR208
go.drugbank.com/drugs/DB05106InvestigationalIt contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.